Development of [89Zr]DFO-elotuzumab for immunoPET imaging of CS1 in multiple myeloma

In Vivo Quantitative Assessment of Therapeutic Response to Bortezomib Therapy in Disseminated Animal Models of Multiple Myeloma With [18F]FDG and [64Cu]LLP2A PET

“…Recently there have been exciting developments in the sphere of MM imaging. Non-invasive imaging modalities such as PET/CT or PET/MRI have been extensively used to investigate bone lesions and metastasis in MM [22,42,43]. Our group has previously showed that antibody-based PET nuclear agents, [ 89 Zr]daratumumab and [ 89 Zr]elotuzumab targeted to overexpressed proteins CD38 and CS1 respectively on myeloma cells can be used as companion diagnostics for preclinical imaging of MM [22,42].…”

“…Non-invasive imaging modalities such as PET/CT or PET/MRI have been extensively used to investigate bone lesions and metastasis in MM [22,42,43]. Our group has previously showed that antibody-based PET nuclear agents, [ 89 Zr]daratumumab and [ 89 Zr]elotuzumab targeted to overexpressed proteins CD38 and CS1 respectively on myeloma cells can be used as companion diagnostics for preclinical imaging of MM [22,42]. Ulaner et al demonstrated the rst-in-human use of [ 89 Zr]daratumumab in measuring MM burden, evaluating minimal residue disease (MRD), and assessing daratumumab therapy response [44].…”

“…Despite the frequent use of [ 18 F]FDG in MM imaging, this metabolic tracer has limited use in therapy response monitoring. PET imaging using [ 18 F]FDG can lead to false positive signal due to increased uptake in a treatment setting due to are, and false negatives due to decreased uptake in hypometabolic MM lesions [22,48]. To overcome these limitations, we propose the use of a non-[ 18 F]FDG PET tracer to evaluate therapy response in MM.…”

“…However, despite being the PET gold standard for MM imaging, [ 18 F]FDG imaging has certain limitations in MM. [ 18 F]FDG is unable to distinguish between malignant cells and in ammation following therapy ( are reaction to steroids), leading to false positive results [21,22]. Contrarily, in metabolically low MM lesions, [ 18 F]FDG/PET invariably results in underestimation of tumor burden [22].…”

“…[ 18 F]FDG is unable to distinguish between malignant cells and in ammation following therapy ( are reaction to steroids), leading to false positive results [21,22]. Contrarily, in metabolically low MM lesions, [ 18 F]FDG/PET invariably results in underestimation of tumor burden [22]. [ 18 F]FDG/PET also has less than optimal e cacy for detecting diffuse bone marrow in ltration in patients with MM [20].…”